drugset

drugset / Trial / NCT06662760

Clinical Trial of TQB3002 in Patients With Advanced Cancers

NCT06662760 ↗

Phase 1 Recruiting 150 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers

Timeline

Start: 2024-12-09
Primary completion: 2025-11
Completion: 2026-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQB3002	Small molecule	—	—

Indications